A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
A gynecologic oncology ethics education program intended to engage students and foster open exchange was designed after review of ethics consults at a tertiary cancer center over a 15-year period.
AMA J Ethics. 2015;17(9):834-838. doi:
10.1001/journalofethics.2015.17.9.medu1-1509.
The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions.